Male hypogonadism is decreased production of testosterone, sperm, or both or, rarely, decreased response to testosterone, resulting in delayed puberty, infertility, or both. Diagnosis is by measurement of serum testosterone, luteinizing hormone, and follicle-stimulating hormone and by stimulation tests with human chorionic gonadotropin or gonadotropin-releasing hormone. Treatment depends on the cause.
Classification of Male Hypogonadism in Children
There are 3 types of hypogonadism: primary, secondary, and a type caused by defective androgen action, primarily due to defective androgen receptor activity.
Primary hypogonadism
In primary (hypergonadotropic) hypogonadism, damage to the Leydig cells impairs testosterone production, damages the seminiferous tubules, or does both; oligospermia or azoospermia and elevated gonadotropins result.
The most common cause is:
Other causes are disorders of sexual development such as gonadal dysgenesis (rare), cryptorchidism, bilateral anorchia, Leydig cell aplasia, Noonan syndrome, myotonic dystrophy, and disorders of androgen synthesis (eg, congenital adrenal hyperplasia).
Less common acquired causes include orchitis due to mumps, testicular torsion, chemotherapy with alkylating medications, and trauma.
Klinefelter syndrome is seminiferous tubule dysgenesis associated with the 47,XXY karyotype, in which an extra X chromosome is acquired through maternal or, to a lesser extent, paternal meiotic nondisjunction. The syndrome is usually identified at puberty, when inadequate sexual development is noted (typically very small, firm testes), prenatally with amniocentesis, or later, when infertility is investigated. Gynecomastia often occurs due to gonadotropin-induced increase in aromatase activity and subsequent conversion of testosterone to estradiol. Diagnosis is based on elevated gonadotropin levels and low to low-normal testosterone levels.
Errors of sex determination and gonadal development, such as gonadal dysgenesis (46,XX or 46,XY) and testicular and ovotesticular disorders of sex development, represent rare forms of male hypogonadism. They may result in a male or undervirilized male phenotype, ambiguous genitals at birth, and some degree of testicular and spermatogenic failure.
In cryptorchidism, one or both testes are undescended. Etiology is usually unknown, but this disorder can be associated with endocrine disorders and genetic conditions (eg, Klinefelter syndrome, Kallman syndrome). Sperm counts may be slightly low if one testis is undescended but are almost always very low if both are undescended. Patients have a significant risk of later infertility if germ cells are not found on biopsy, particularly in bilateral undescended testes (1).
This light micrograph shows a section of atrophy in tissue from an undescended testis (cryptorchidism). Here, the seminiferous tubules are atrophied, fibrous tissue has formed between the tubules, and almost no sperm cells are being produced.
BIOPHOTO ASSOCIATES/SCIENCE PHOTO LIBRARY
In bilateral anorchia (vanishing testes syndrome), the testes were presumably present but were resorbed before or after birth. External genitals and wolffian structures are normal, but müllerian duct structures are lacking. Thus, testicular tissue must have been present during the first 12 weeks of embryogenesis because testicular differentiation occurred and testosterone and müllerian-inhibiting factor were produced.
Leydig cell aplasia occurs when congenital absence of Leydig cells causes partially developed or ambiguous external genitals. Although wolffian ducts develop to some extent, testosterone production is insufficient to induce normal male differentiation of the external genitals. Müllerian ducts are absent because of normal production of anti-müllerian hormone by Sertoli cells. Gonadotropin levels are high with low testosterone levels.
Noonan syndrome may occur sporadically or as an autosomal dominant inherited RASopathy. Noonan syndrome is relatively common, occurring in approximately 1 in 1000 to 2500 people. Both boys and girls can be affected (2, 3). Phenotypic abnormalities include hyperelasticity of the skin, hypertelorism, ptosis, low-set ears, short stature, shortened fourth metacarpals, high-arched palate, and primarily right-sided cardiovascular anomalies (eg, pulmonic valve stenosis, atrial septal defect). Hearing problems can occur, and affected individuals may have intellectual disability. Testes are often small or cryptorchid. Testosterone levels may be low with high gonadotropin levels.
Defective androgen synthesis is caused by enzyme defects that impair androgen synthesis, which may occur in any of the pathways leading from cholesterol to dihydrotestosterone. These congenital problems may occur in congenital adrenal hyperplasia (eg, steroidogenic acute regulatory [StAR] protein deficiency, 17alpha-hydroxylase deficiency, 3beta-hydroxysteroid dehydrogenase deficiency) when the same enzyme defect occurs in the adrenal glands and the testes, resulting in defective androgen activity and ambiguous external genitals of varying degrees.
Secondary hypogonadism
Causes of secondary (hypogonadotropic) hypogonadism include panhypopituitarism, hypothalamic or pituitary tumors, isolated gonadotropin deficiency, Kallmann syndrome, isolated luteinizing hormone deficiency, congenital syndromes associated with developmental delay (eg, Prader-Willi syndrome), and functional and acquired disorders of the central nervous system (eg, trauma, infection, infiltrative disease such as Langerhans cell histiocytosis). Causes of secondary hypogonadism must be differentiated from constitutional delay of puberty, which is a functional, temporary form of secondary hypogonadism. Several acute disorders and chronic systemic disorders (eg, chronic renal insufficiency, anorexia nervosa) may lead to functional hypogonadotropic hypogonadism, which resolves after recovery from the underlying disorder. Hypogonadism is also more common among long-term survivors of childhood cancers treated with craniospinal irradiation.
Panhypopituitarism may occur congenitally or anatomically (eg, in septo-optic dysplasia or Dandy-Walker malformation), causing deficiency of hypothalamic-releasing factors or pituitary hormones. Acquired hypopituitarism may result from tumors, neoplasia, or their treatment, vascular disorders, infiltrative disorders (eg, sarcoidosis, Langerhans cell histiocytosis), infections (eg, encephalitis, meningitis), or trauma. Hypopituitarism in childhood may cause delayed growth, hypothyroidism, argininevasopressin deficiency (diabetes insipidus), hypoadrenalism, and lack of sexual development when puberty is expected. Hormone deficiencies, whether originating in the anterior or posterior pituitary, may be varied and multiple.
Kallmann syndrome causes approximately 60% of congenital forms of hypogonadotropic hypogonadism (4). It is characterized by anosmia/hyposmia due to aplasia or hypoplasia of the olfactory lobes and by hypogonadism due to deficiency of hypothalamic gonadotropin-releasing hormone (GnRH). It occurs when fetal GnRH neurosecretory neurons do not migrate from the olfactory placode to the hypothalamus. The genetic defect is known; inheritance is classically X-linked but can also be autosomal dominant or autosomal recessive (5). Other manifestations include microphallus, cryptorchidism, midline defects, and unilateral kidney agenesis. Presentation is clinically heterogeneous, and some patients have a normal ability to detect odors.
Isolated luteinizing hormone (LH) deficiency is a rare cause of hypogonadism due to monotropic loss of LH secretion in boys; follicle-stimulating hormone (FSH) levels are normal. At puberty, growth of the testes is normal because most testicular volume consists of seminiferous tubules, which respond to FSH. Spermatogenesis may occur as tubular development proceeds. However, absence of LH results in Leydig cell atrophy and testosterone deficiency. Therefore, patients do not develop normal secondary sexual characteristics, but they continue to grow, reaching eunuchoidal proportions (arm span exceeds height by 5 cm; pubic to floor length exceeds crown to pubic length by > 5 cm) because the epiphyses do not close.
Prader-Willi syndrome is characterized by diminished fetal activity, muscular hypotonia, and growth and weight faltering (failure to thrive) during early childhood followed later by obesity, obsessive-compulsive behaviors, intellectual disability, and hypogonadotropic hypogonadism. Approximately 70% of people who have Prader-Willi syndrome are missing part of chromosome 15, and approximately 25% of people who have this syndrome have problems with the function of chromosome 15 (6). The remaining 5% of cases result from other causes. Growth and weight faltering due to hypotonia and feeding difficulties during infancy resolves and then uncontrollable hyperphagia develops, which causes excessive weight gain and psychological problems; plethoric obesity becomes the most striking feature. Rapid weight gain continues into adulthood; stature remains short with more than 50% having caused by growth hormone deficiency when formally tested. Features include emotional lability, poor gross motor skills, facial abnormalities (eg, a narrow bitemporal dimension, almond-shaped eyes, a mouth with thin upper lips and down-turned corners), and skeletal abnormalities (eg, scoliosis, kyphosis, osteopenia). Hands and feet are small. Other features include cryptorchidism and a hypoplastic penis and scrotum.
Classification references
1. Kolon TF, Herndon CD, Baker LA, et al. Evaluation and treatment of cryptorchidism: AUA guideline [reaffirmed 2025]. J Urol. 2014;192(2):337-345. doi:10.1016/j.juro.2014.05.005
2. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126(4):746-759. doi:10.1542/peds.2009-3207
3. Zenker M, Edouard T, Blair JC, Cappa M. Noonan syndrome: improving recognition and diagnosis. Arch Dis Child. 2022;107(12):1073-1078. doi:10.1136/archdischild-2021-322858
4. Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250-1263. doi:10.1016/S0140-6736(13)61126-5
5. Kumar Yadav R, Qi B, Wen J, Gang X, Banerjee S. Kallmann syndrome: Diagnostics and management. Clin Chim Acta. 2025;565:119994. doi:10.1016/j.cca.2024.119994
6. MedlinePlus: Prader-Willi syndrome. May 13, 2022. Accessed April 16, 2026.
Symptoms and Signs of Male Hypogonadism in Children
Clinical presentation depends on whether, when, and how testosterone and sperm production are affected. (For presentation in adulthood, see Symptoms and Signs of Male Hypogonadism.)
If androgen deficiency or defects in androgen activity occur during the first trimester (< 12 weeks gestation), differentiation of internal wolffian ducts and external genitals is inadequate. Presentation may range from ambiguous external genitals to normal-appearing female external genitals. Androgen deficiency during the second and third trimesters may cause a microphallus and partially or completely undescended testes.
Androgen deficiency that develops early in childhood has few consequences, but if it occurs when puberty is expected, secondary sexual development is impaired. Such patients have poor muscle development, a high-pitched voice, inadequate phallic and testicular growth, a small scrotum, sparse pubic and axillary hair, and absent body hair. They may develop gynecomastia and grow to eunuchoidal body proportions (arm span exceeds height by 5 cm; pubic to floor length exceeds crown to pubic length by > 5 cm) because fusion of the epiphyses is delayed and long bone growth continues.
Diagnosis of Male Hypogonadism in Children
Measurement of testosterone, LH, and FSH
Karyotyping (for primary hypogonadism)
Diagnosis of male hypogonadism in children is often suspected based on developmental abnormalities or delayed puberty but requires confirmation by testing, including measurement of testosterone, LH, and FSH. LH, and especially FSH. FSH levels are more sensitive than testosterone levels, which can vary day-to-day, especially for detecting primary hypogonadism (1). Testing should be performed in the morning and requires pediatric-specific assays (often labeled as ultrasensitive or immunochemiluminometric [ICMA]).
LH and FSH levels also help determine whether hypogonadism is primary or secondary:
High levels, even with low-normal testosterone levels, indicate primary (hypergonadotropic) hypogonadism.
Levels that are low or lower than expected for the testosterone level indicate secondary (hypogonadotropic) hypogonadism.
In primary (hypergonadotropic) hypogonadism, it is important to determine the karyotype to investigate for Klinefelter syndrome.
Elevated serum FSH levels with normal serum testosterone and LH levels typically indicate impaired spermatogenesis but not impaired testosterone production.
In boys with short stature, delayed pubertal development, low testosterone, and low FSH and LH levels may indicate constitutional delay. Unlike constitutional delay, in which there is a transient decrease in these hormones that normalizes with time, the gonadotropins and testosterone do not normalize with time in hypogonadism.
Interpretation of testosterone, FSH, and LH levels for diagnosis of hypogonadism requires an understanding of how the levels vary. Before puberty, serum testosterone levels are < 20 ng/dL (< 0.7 nmol/L); in adulthood, levels are > 300 to 1200 ng/dL (12 to 42 nmol/L). Serum testosterone secretion is primarily circadian. Levels peak in the morning in the early and middle stages of puberty, but higher levels can be detected in the afternoon as well as in the morning in later puberty. A single sample obtained in the morning can establish that circulating testosterone levels are normal. Because 96 to 98% of testosterone is bound to carrier proteins in serum (usually sex hormone–binding globulin) (2), alterations in these protein levels alter total testosterone levels. Measurement of total serum testosterone (protein bound and free) is usually the most accurate indicator of testosterone secretion.
Although serum LH and FSH levels are pulsatile, testing can be valuable. Puberty begins when GnRH secretion increases and serum LH rises disproportionately to FSH. Early in puberty, early morning levels are preferred. Serum LH levels are usually below 0.2 to 0.3 mIU/mL (0.2 to 0.3 units/L) before puberty and range from 2 to 12 mIU/mL (2 to 12 units/L) during later stages of puberty and into adulthood. Serum FSH levels are usually < 3 mIU/mL (< 3 units/L) before puberty and fluctuate between 5 and 10 mIU/mL (5 and 10 units/L) during the second half of puberty and into adulthood. There is no specific threshold between prepubertal and pubertal FSH values, but typically levels > 20 mIU/ml (20 units/L) are seen in primary gonadal insufficiency.
Measurement of inhibin B and anti-müllerian hormone levels can help assess gonadal function in boys with suspected hypogonadism, both primary and secondary (3, 4). Both are functional markers of Sertoli cells, which play an important role in spermatogenesis and account for the majority of testicular growth before puberty. Unlike LH and FSH, these markers are easily measured before puberty. For boys with delayed puberty and suspected secondary hypogonadism, low levels of inhibin B, which normally rise at puberty, are more suggestive of secondary hypogonadism than constitutional delay. Anti-müllerian hormone levels are more helpful in the detection of functional testicular tissue during infancy (eg, cryptorchidism) but are less useful in evaluations of older males with delayed puberty as levels decline due to suppression from androgens.
The human chorionic gonadotropin (hCG) stimulation test is performed to assess the presence and secretory ability of testicular tissue. Multiple protocols exist. In one protocol, a one-time dose of hCG 100 units/kg IM is given. Because hCG stimulates Leydig cells to produce testosterone (as does LH, with which it shares a structural subunit), testosterone levels should double after 3 to 4 days.
Diagnosis references
1. De Silva NL, Papanikolaou N, Grossmann M, et al. Male hypogonadism: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2024;12(10):761-774. doi:10.1016/S2213-8587(24)00199-2
2. Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications. Endocr Rev. 2017;38(4):302-324. doi:10.1210/er.2017-00025
3. Varimo T, Miettinen PJ, Känsäkoski J, et al. Congenital hypogonadotropic hypogonadism, functional hypogonadotropism or constitutional delay of growth and puberty? An analysis of a large patient series from a single tertiary center. Hum Reprod. 2017;32(1):147-153. doi: 10.1093/humrep/dew294
4. Rohayem J, Nieschlag E, Kliesch S, Zitzmann M. Inhibin B, AMH, but not INSL3, IGF1 or DHEAS support differentiation between constitutional delay of growth and puberty and hypogonadotropic hypogonadism. Andrology. 2015;3(5):882-887. doi: 10.1111/andr.12088
Treatment of Male Hypogonadism in Children
Surgery as needed
Hormone (testosterone) replacement
Cryptorchidism is corrected early (within the first year of life) to reduce concerns about cancer developing in later adulthood and to prevent testicular torsion. Surgical repositioning of testis or testes into the scrotum may reduce the potential for infertility but does not eliminate it (1).
For secondary hypogonadism, any underlying pituitary or hypothalamic disorder is treated. Overall, the goal is to provide androgen replacement starting with a low dose and progressively increasing the dose over 18 to 24 months. Treatment is started at an appropriate age for normal onset of puberty, often around 12 years of age.
Adolescent boys with androgen deficiency (either primary or secondary) should be given long-acting injectable testosterone enanthate or testosterone cypionate every 4 weeks; the dose is increased every 2 to 4 weeks over 18 to 24 months (2). Traditionally, testosterone is given by intramuscular injection but can also be given by subcutaneous injection, or by transdermal patch or gel in older boys (> 18 years). Treatment choice can be determined based on patient preference, but injections are preferred as doses are being increased. Some previous forms of oral testosterone are associated with liver toxicity due to chemical properties; agents that bypass first-pass liver metabolism are available and should potentially reduce hepatotoxicity, but they are not available for patients < 18 years of age (3, 4).
Treatment of Kallmann syndrome with hCG, sometimes in combination with FSH, can correct cryptorchidism and establish fertility (5). Puberty is typically induced using testosterone injectable or gel. In other permanent cases of hypogonadotropic hypogonadism, testosterone has also been the traditional treatment; it promotes virilization but not testicular growth or spermatogenesis. Gonadotropin therapy, typically FSH, in combination with hCG, may help with testicular development and spermatogenesis, but consensus is lacking on the use of these medications in this age group for pubertal induction or completion (6).
In isolated LH deficiency, testosterone, via conversion to estrogen by aromatase, induces normal epiphyseal closure.
Patients with Prader-Willi syndrome may be treated with human growth hormone in addition to gonadal hormone replacement. Several studies have shown these treatment regimens are beneficial for growth, body composition, and improved motor development (7, 8).
Treatment references
1. Kolon TF, Herndon CD, Baker LA, et al. Evaluation and treatment of cryptorchidism: AUA guideline [reaffirmed 2025]. J Urol. 2014;192(2):337-345. doi:10.1016/j.juro.2014.05.005
2. De Silva NL, Papanikolaou N, Grossmann M, et al. Male hypogonadism: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2024;12(10):761-774. doi:10.1016/S2213-8587(24)00199-2
3. National Library of Medicine. DailyMed. Label: JATENZO- testosterone undecanoate capsule, liquid filled. September 15, 2025. Accessed April 16, 2026.
4. Vogiatzi M, Tursi JP, Jaffe JS, Hobson S, Rogol AD. Testosterone Use in Adolescent Males: Current Practice and Unmet Needs. J Endocr Soc. 2020;5(1):bvaa161. Published 2020 Oct 30. doi:10.1210/jendso/bvaa161
5. Kumar Yadav R, Qi B, Wen J, Gang X, Banerjee S. Kallmann syndrome: Diagnostics and management. Clin Chim Acta. 2025;565:119994. doi:10.1016/j.cca.2024.119994
6. Alexander EC, Faruqi D, Farquhar R, et al. Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis. Eur J Endocrinol. 2024;190(1):S1-S11. doi:10.1093/ejendo/lvad166
7. Rosenberg AGW, Passone CGB, Pellikaan K, et al. Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis. J Clin Endocrinol Metab. 2021;106(10):3068-3091. doi:10.1210/clinem/dgab406
8. Tauber M, Hoybye C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol. 2021;9(4):235-246. doi:10.1016/S2213-8587(21)00002-4
Key Points
In primary male hypogonadism, a congenital (or rarely acquired) testicular disorder impairs testosterone production and/or damages the seminiferous tubules.
In secondary male hypogonadism, congenital or acquired disorders of the hypothalamus or pituitary cause gonadotropin deficiency and failure to stimulate normal testes; secondary male hypogonadism must be differentiated from constitutional delay.
Manifestations and their timing vary widely depending on when testosterone production is affected.
Prenatal androgen deficiency may result in manifestations ranging from partially undescended testes, microphallus, and ambiguous external genitals to normal-appearing female external genitals.
Androgen deficiency that occurs when puberty is expected impairs secondary sexual development.
Diagnose androgen deficiency by measurement of testosterone, luteinizing hormone, and follicle-stimulating hormone levels.
Treat with hormone replacement and surgery as needed.
Drug Information for the Topic
